clinical trial · NCT07035886
A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
Takeda·—·recruiting·n = 600
Colorectal CancerNo intervention
brief summary
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.
started
Sep 29, 2025
primary completion
Sep 1, 2029
completion
Mar 1, 2031
last updated
Feb 27, 2026
official title
Post-Marketing Surveillance (Usage Results Study) of Fruzaqla Capsule (Fruquintinib) for the Approved Indications in South Korea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol